NEW YORK--(BUSINESS WIRE)--Manhattan Scientifics, Inc. (MHTX: OTCQ: BB) today issued an update on the status of the company and its future plans.
After successfully spinning-out and taking public its cancer diagnostic technology (IBX) and exclusively licensing its other metals technology, Manhattan Scientifics will enter its third phase of activity – to acquire a substantial technology company and to uplist MHTX to a national securities exchange such as the Nasdaq Capital Market.
We remain optimistic about prospects for commercialization of our two nanotechnology developments and we are actively engaged in early discussions with prospective companies that wish to go public via the process of merging with us.
About Manhattan Scientifics, Inc.
Manhattan Scientifics Inc. (www.mhtx.com) is focused on commercialization of disruptive technologies in the nano medicine space.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.